Boost for Sanofi's MS franchise with NICE U-turn on Aubagio
This article was originally published in Scrip
Executive Summary
A day after requesting a series of clarifications on another multiple sclerosis drug, NICE said on 6 December in final draft guidance that it intends to recommend Aubagio (Sanofi's teriflunomide) for adults with active relapsing-remitting MS.